- Home
- HTLD vs VSTM Comparison
HTLD vs VSTM Comparison
Compare HTLD & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HTLD | VSTM |
|---|---|---|
| Founded | 1978 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.1M | 723.8M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | HTLD | VSTM |
|---|---|---|
| Price | $10.39 | $6.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $9.25 | ★ $13.38 |
| AVG Volume (30 Days) | 595.4K | ★ 2.1M |
| Earning Date | 01-28-2026 | 11-04-2025 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $868,930,000.00 | $13,379,000.00 |
| Revenue This Year | N/A | $208.54 |
| Revenue Next Year | N/A | $251.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 33.79 |
| 52 Week Low | $7.00 | $4.01 |
| 52 Week High | $12.19 | $11.25 |
Technical Indicators
Market Signals| Indicator | HTLD | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 73.37 | 35.27 |
| Support Level | $10.05 | $6.68 |
| Resistance Level | $10.54 | $8.35 |
| Average True Range (ATR) | 0.28 | 0.58 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 97.55 | 5.23 |
Price Performance
Historical ComparisonAbout HTLD Heartland Express Inc.
Heartland Express Inc is engaged in providing truckload services across the United States, Mexico, and Canada. These truckload services are asset-based transportation services in the dry van truckload market. The company offers truckload temperature-controlled transportation services, and Mexico logistics services. A majority of its customers represent the consumer goods, appliances, food products, and automotive industries.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.